Research reportEffects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets
Introduction
In schizophrenia, cognitive impairment is one of the core symptoms affecting functional outcomes such as social adjustment and employment [1], [2]. Therefore, it is very important to improve the cognitive dysfunction of schizophrenia patients; however, atypical antipsychotics have insufficient effects in this patient group [3], [4]. On the other hand, previous preclinical studies have shown that atypical antipsychotics improved cognitive function [5], [6]. In humans, cognitive function is controlled by the prefrontal cortex (PFC), but in rodents it is mainly dependent on the hippocampus. The rodent PFC is not the same as that of primates, for example, the rodent PFC is less developed [7], [8], so it is possible that rodents execute cognitive processes through different neuronal pathways than primates, which might result in differences in drug effects between rodents and humans. To improve the predictive accuracy of models used to assess the clinical effects of drugs on higher brain functions, such as cognition, it is important to evaluate drug effects not only in rodents but also in non-human primates (NHP), whose brain structures are closer to those of humans.
N-methyl-d-aspartic acid (NMDA) receptor antagonists such as ketamine and phencyclidine (PCP) have been found to induce schizophrenia-like symptoms, for example, hallucinations, paranoia, formal thought disorders, and cognitive impairment in healthy human subjects [9], [10]. In addition, in evaluations of cognitive function in human volunteers the administration of NMDA receptor antagonists resulted in worse performance in the n-back test [11], which is PFC-dependent [12], [13], so it is thought that the cognitive dysfunction observed in schizophrenia results from abnormal glutamatergic neuronal transmission due to the hypofunction of NMDA receptors in the PFC. In addition, it has also been reported that NMDA receptor antagonists induce cognitive impairment in NHP [14], [15], [16]. Based on these facts, a NHP model of NMDA receptor antagonist-induced cognitive dysfunction could be a useful tool for translational research. Large monkeys have been used in most previous preclinical studies of cognition; however, they are difficult to handle and require a large quantity of test drugs so in this study we used common marmosets (small monkeys) instead. As the brain anatomy and genetic and immunological characteristics of marmosets are similar to those of humans, they have recently been recognized as useful experimental animals. To the best of our knowledge, no marmoset model of ketamine-induced cognitive dysfunction has been reported although similar models involving rodents and other monkey species have been developed [15], [17], [18].
The Cambridge Neuropsychological Test Automated Battery (CANTAB) is used to evaluate cognitive function and is able to assess memory, attention, and executive function. In this study, we tried to develop a marmoset model of ketamine-induced spatial working memory (SWM) deficiency using the CANTAB SWM test with the aim of constructing a drug evaluation system that is convenient to use and displays a high level of predictive validity. The SWM test is one of the components of the CANTAB and is often used in clinical research [19]. Schizophrenia patients display impairment in the SWM test [20] so it is important to improve this deficit in order to improve their quality of life. In addition, using the abovementioned experimental system, we tested the effects of a selective and full agonist of the dopamine D1 receptor (SKF-81297) on ketamine-induced cognitive dysfunction, as there is a lot of evidence that D1 agonists are effective against cognitive dysfunction in schizophrenia [21], [22], [23].
Section snippets
Effect of training on the marmosets’ success rate in the CANTAB SWM test
At the beginning of the training program, the marmosets could not accurately execute the 2-square task. It took 1–3 months for their success rate to reach a level that would allow them to be used in the subsequent experiments.
Determination of the optimal ketamine dose using the 1-circle task of the CANTAB
Ketamine immediately induced gait disorders after its injection at the dosages described in Table 1, but 30 min later, the gait disorder had disappeared. All of the marmosets were able to complete the 1-circle task within a mean of 60 s in each trial, as shown in Table 1.
Effects of a D1 agonist on ketamine-induced cognitive impairment in the CANTAB SWM test
As
Discussion
In this study, we constructed a model of ketamine-induced spatial working memory deficiency, in which we subjected marmosets to the CANTAB SWM test, with the aim of developing a drug evaluation system that is more convenient than the current methods and has high predictive validity. In addition, we showed that a D1 agonist was effective against ketamine-induced cognitive impairment. To the best of our knowledge, no such ketamine-induced cognitive dysfunction model involving marmosets has been
Animals
Five female adult common marmosets (Callithrix jacchus, 4–10 years old) obtained from CLEA Japan Inc. (Tokyo, Japan) were used in this study. The animals were housed in an air-conditioned room kept at a temperature of 28 ± 2 °C and a humidity of 50 ± 20% under a 12:12 light/dark cycle (lights off at 19:00). Food (CMS-1M, CLEA Japan, Inc.) was administered once daily, and water was available ad libitum. After the end of final experiments, animals were used in other evaluation. All experimental
References (35)
- et al.
Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment
Psychiatric Clinics of North America
(2003) - et al.
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
Biological Psychiatry
(2004) - et al.
Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat
Behavioural Brain Research
(2007) - et al.
Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice
Pharmacology Biochemistry and Behavior
(2011) - et al.
Rodent models of prefrontal cortical function
Trends in Neurosciences
(2002) - et al.
Do rats have a prefrontal cortex?
Behavioural Brain Research
(2003) - et al.
Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers
Biological Psychiatry
(1998) - et al.
Acute behavioral effects of MK-801 in rhesus monkeys: assessment using an operant test battery
Pharmacology Biochemistry and Behavior
(1994) - et al.
A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists
Biochemical Pharmacology
(2009) - et al.
Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration
Neuropharmacology
(2012)
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism
Pharmacology & Therapeutics
Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB
European Psychiatry
The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia
Biological Psychiatry
Planning and spatial working memory following frontal lobe lesions in man
Neuropsychologia
Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
Neuroscience
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
Schizophrenia Bulletin
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness
Journal of Clinical Psychiatry
Cited by (34)
Behavioral shaping of rhesus macaques using the Cambridge neuropsychological automated testing battery
2020, Journal of Neuroscience MethodsCitation Excerpt :Due to the language free design aspect of these tasks, the CANTAB is also used to study cognition in non-human primates (NHPs). Marmosets (Spinelli et al., 2005; Spinelli et al., 2004; Nakako et al., 2013a), cynomolgus (Kromrey et al., 2015a; Kromrey et al., 2015b), and rhesus macaques (Taffe et al., 1999; Weed et al., 2004; Wright et al., 2013; Weed et al., 1999; Marino and Levy, 2019) have all been successfully trained to perform various NHP-adapted versions of the CANTAB tasks, and the CANTAB has also been used to quantify cognitive changes in NHP models of disease (Taffe et al., 1999; Weed et al., 2004; Schneider et al., 2015; Schneider, 2006; Nagahara et al., 2010). The ability to test the same cognitive tasks in both NHP disease models and human patient populations makes the CANTAB a valuable translational research tool.
The marmoset as a model for visual neuroscience
2018, The Common Marmoset in Captivity and Biomedical ResearchKetamine abuse potential and use disorder
2016, Brain Research BulletinThe dopamine D<inf>1</inf> receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets
2016, Behavioural Brain ResearchSustained performance by common marmosets in a delayed matching to position task with variable stimulus presentations
2016, Behavioural Brain Research